<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4353274/results/search/test_trace/results.xml">
  <result pre="the reuse is restricted to noncommercial purposes. For commercial reuse," exact="contact" post="support@pulsus.com This article represents the second update to the"/>
  <result pre="have not adequately addressed the significantly greater benefit of NI" exact="treatment" post="in very ill hospitalized patients, nor the greater benefit"/>
  <result pre="very ill hospitalized patients, nor the greater benefit of earlier" exact="treatment" post="after onset of symptoms (4). Earlier therapy with oral"/>
  <result pre="received zanamivir within 30 h (3). In low-risk outpatients, NI" exact="treatment" post="of mild influenza illness may be considered but is"/>
  <result pre="to acute care facilities with influenza-like illness (ILI) and require" exact="treatment" post="with NI. To date, the majority of the predominating"/>
  <result pre="clinic (10). Of course, these values vary depending on the" exact="prevalence" post="of influenza in the community relative to other respiratory"/>
  <result pre="polymerase chain reaction (PCR) is preferred to direct fluorescent antigen" exact="detection" post="(DFA) due to its greater sensitivity. A nasopharyngeal swab"/>
  <result pre="aspirate specimen for PCR should also be performed. Multiplex PCR" exact="testing" post="allows for the diagnostic confirmation of other respiratory viruses,"/>
  <result pre="of influenza-like symptoms. However, in severe illness requiring hospitalization, oseltamivir" exact="treatment" post="has been shown to reduce mortality even if treatment"/>
  <result pre="oseltamivir treatment has been shown to reduce mortality even if" exact="treatment" post="is started up to 96 h after the start"/>
  <result pre="clinical assessment and collection of appropriate specimens for virus testing," exact="treatment" post="should be started immediately, most frequently with oseltamivir orally."/>
  <result pre="endotracheal samples should be sent for viral PCR and susceptibility" exact="testing" post="for oseltamivir resistance. Suspected oseltamivir resistance should prompt a"/>
  <result pre="a switch to intravenous zanamivir until results of antiviral susceptibility" exact="testing" post="are available. Repeated viral testing should be performed if"/>
  <result pre="until results of antiviral susceptibility testing are available. Repeated viral" exact="testing" post="should be performed if the clinical condition fails to"/>
  <result pre="document. However, if a patient presents with an acute respiratory" exact="infection" post="on a background of an influenza outbreak, and a"/>
  <result pre="PATIENT WITH SUSPECTED INFLUENZA? A detailed discussion of the appropriate" exact="infection" post="control measures for the management of patients with suspected"/>
  <result pre="this document. However, the following measures are generally employed. Patient" exact="isolation" post="During an influenza outbreak, all individuals with ILI admitted"/>
  <result pre="placed on Droplet and Contact precautions pending the results of" exact="testing" post="on the NP swab. Personal protective equipment (PPE) All"/>
  <result pre="All medical personnel should use appropriate PPE for droplet and" exact="contact" post="precautions prior to contact with persons with ILI. Influenza"/>
  <result pre="use appropriate PPE for droplet and contact precautions prior to" exact="contact" post="with persons with ILI. Influenza virus can be transmitted"/>
  <result pre="be transmitted through large droplet spread from coughing or mucosal" exact="contact" post="with contaminated surfaces or fomites. Whether vaccinated or unvaccinated,"/>
  <result pre="regardless of their vaccine status, who have had unprotected close" exact="contact" post="with a patient with ILI, may be offered either"/>
  <result pre="hospitalized patients identified &amp;gt;48 h after exposure, observation and early" exact="treatment" post="if symptoms arise is the preferred strategy. Close observation"/>
  <result pre="symptoms arise is the preferred strategy. Close observation and early" exact="treatment" post="is recommended for individuals who choose not to receive"/>
  <result pre="None. References REFERENCES 1.NicholsonKAokiFYOsterhausADet al.Efficacy and safety of oseltamivir in" exact="treatment" post="of acute influenza: A randomized controlled trialLancet200035518455010866439 2.collab: The"/>
  <result pre="GroupRandomised trial of efficacy and safety of inhaled zanamivir in" exact="treatment" post="of influenza A and B virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy"/>
  <result pre="al.Efficacy and safety of the neuraminidase inhibitor zanamivir in the" exact="treatment" post="of influenzaviris infectionsNew Engl J Med1997337874809302301 4.JeffersonTJonesMDoshiPSpencerEAOnakpoyaIHeneghanCJOseltamivir for influenza"/>
  <result pre="pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and zanamivir" exact="treatment" post="of influenza Updated from: The use of antiviral drugs"/>
  <result pre="*Please note that antivirals are not authorized for the routine" exact="treatment" post="of seasonal influenza illness in infants &amp;lt;1 year of"/>
  <result pre="mg (two 5 mg inhalations) twice dailyChildren (≥7 years for" exact="treatment" post="and chemoprophylaxis) 10 mg (two 5 mg inhalations) once"/>
  <result pre="adults (13–15). The American Academy of Pediatrics recommended an oseltamivir" exact="treatment" post="dose of 3.5 mg/kg orally twice daily for infants"/>
  <result pre="However, if weight is not known, dosing by age for" exact="treatment" post="of influenza (give two doses per day) or prophylaxis"/>
  <result pre="be necessary: 0–3 months = 12 mg per dose for" exact="treatment" post="(not for prophylaxis); 3–5 months = 20 mg per"/>
  <result pre="be consulted in the case of premature infants for whom" exact="treatment" post="with oseltamivir is being considered. The current weight-based dosing"/>
  <result pre="of bronchospasm. TABLE 2 Recommended oseltamivir regimens for prevention and" exact="treatment" post="of adult patients with renal impairment (Tamiflu® Product Monograph,"/>
 </snippets>
</snippetsTree>
